Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study
| Autor: | Kazuho Miyashita, Ayumi Numata, Jun Taguchi, Hideyuki Koharazawa, Takayuki Sakuma, Yoshimi Ishii, Rika Sakai, Yuki Nakajima, Katsumichi Fujimaki, Takuya Miyazaki, Hideaki Nakajima, Hiroyuki Takahashi, Hiroyuki Fujita, Yukako Hattori, Chizuko Hashimoto, Ayako Matsumura, Sachiya Takemura |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Limited Stage
Oncology medicine.medical_specialty Chemotherapy Hematology business.industry medicine.medical_treatment Retrospective cohort study medicine.disease Breast Diffuse Large B-Cell Lymphoma Lymphoma Primary Breast Lymphoma Internal medicine medicine Original Article business Diffuse large B-cell lymphoma |
| Zdroj: | Indian J Hematol Blood Transfus |
| ISSN: | 0971-4502 |
| Popis: | We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL (n = 11), limited stage SBL (LSBL; n = 6), and advanced stage SBL (ASBL, n = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group (P = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, P = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS (P = 0.01) and PFS (P = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink